High Plasma TIMP-1 and Serum CEA Levels during Combination Chemotherapy for Metastatic Colorectal Cancer Are Significantly Associated with Poor Outcome

Publisher： Karger

E-ISSN： 1423-0232|79|1-2|144-149

ISSN： 0030-2414

Source： Oncology, Vol.79, Iss.1-2, 2010-12, pp. : 144-149

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Assessing Prognosis in Metastatic Pancreatic Cancer by the Serum Tumor Marker CA 19-9: Pretreatment Levels or Kinetics during Chemotherapy?

By  

Oncology Research and Treatment, Vol. 30, Iss. 1-2, 2007-01 ,pp. : 39-42

Karger

Access to resources Recommend Favorite

Serum Concentration of Reg IV in Patients with Colorectal Cancer: Overexpression and High Serum Levels of Reg IV Are Associated with Liver Metastasis

By  

Oncology, Vol. 72, Iss. 5-6, 2008-01 ,pp. : 371-380

Karger

Access to resources Recommend Favorite

A Phase II Study of Third-Line Combination Chemotherapy with Bevacizumab Plus S-1 for Metastatic Colorectal Cancer with Mutated KRAS (SAVIOR Study)

By  

Oncology, Vol. 91, Iss. 1, 2016-05 ,pp. : 24-30

Karger

Access to resources Recommend Favorite

Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer

By  

Case Reports in Oncology, Vol. 7, Iss. 2, 2014-05 ,pp. : 316-322

Karger

Access to resources Recommend Favorite

Baseline and On-Treatment Markers Determining Prognosis of First-Line Chemotherapy in Combination with Bevacizumab in Patients with Metastatic Colorectal Cancer

By  

Oncology Research and Treatment, Vol. 40, Iss. 1-2, 2017-01 ,pp. : 21-26

Karger

Access to resources Recommend Favorite